Manhattan, NY- June 04, 2014 – (Techsonian) – Nuvilex, (OTCMKTS:NVLX), announced that world renowned oncologist and gastroenterologist Professor Dr. Matthias Lohr of the famed Karolinska Institute in Stockholm, Sweden, has agreed to play a major role in Nuvilex’s Phase 2b clinical trial in pancreatic cancer to be conducted in Australia, as well as other clinical studies and trials in which Nuvilex will be involved.
Nuvilex Inc (OTCMKTS:NVLX) decreased -0.35% at the price of $0.285 recently on a traded volume of 178,736 shares, in comparison to 2.67 million shares of average trading volume. The company has a total market capitalization of $181.91 million.
Has NVLX Found The Bottom and Ready To Move Up? Find Out Here
NanoTech Entertainment (OTCMKTS:NTEK) declared a technology partnership involving the company’s Nuvola NP-C™ commercial-grade 4K networked and interactive media player and 11Giraffes digital signage Software as a Service (SaaS). Through the partnership, NTEK, 11Giraffes and their respective channel partners will provide a complete, PnP solution for cost-effective managing, programming and delivery of 4K digital signage with the amazing clearness and depth of color that the 4K resolution provides. Going further than full-screen 4K playback, this joint solution will permit multiple Ultra HD and HD video zones, music, apps and various interactivity, as well as touchscreen inputs.
NanoTech Entertainment, Inc. (OTCMKTS:NTEK) plunged -0.74% at the trading price of $0.540 on a traded volume of 1.47 million shares till now, whereas its average trading volume is 2.62 million shares. The Intra-day range for the stock is $0.05 and $0.06.The company has a total market capitalization of $29.23 million.
Has NTEK Found The Bottom And Ready To Gain Momentum? Find Out Here
New Media Insight Group, (OTCBB:NMED),a leader in mobile payments, recently published that it has recently added over twenty new merchants to its Cloud Pay network in the greater Phoenix area.
New Media Insight Group Inc (OTCBB:NMED) dropped down -5.49% at the $1.55 recently. The 52-week range for the stock is $1.00 and $2.70. Its introductory price for the day was $1.75, with the overall traded volume of 27,768 shares.
Why Should Investors Buy NMED After the Recent Fall? Just Go Here and Find Out
MyEcheck Inc (OTCMKTS:MYEC) released financial outcome and issues its annual report for 2013. For the twelve months finished December 31, 2013, net profit was $1,018,693 with revenue from operations at $439,233. Total liabilities were reduced by $718,365.
MyEcheck Inc (OTCMKTS:MYEC) after opening its shares at the price of $0.04, jumped up 6.25%, its recent trading price was $0.0425 for the day. The stock moved on a traded volume of 2.71 million shares, in comparison to 13.82 million shares of average trading volume.
The 52-week range for the stock is $0.01 and $0.08.
Why Should Investors Buy MYEC After The Recent Gain? Just Go Here and Find Out
This entry passed through the Full-Text RSS service — if this is your content and you’re reading it on someone else’s site, please read the FAQ at fivefilters.org/content-only/faq.php#publishers.